Quarterly report pursuant to Section 13 or 15(d)

SEGMENT INFORMATION

v3.22.0.1
SEGMENT INFORMATION
 3 Months Ended
Jan. 31, 2022
Segment Reporting [Abstract]  
SEGMENT INFORMATION

 

10. SEGMENT INFORMATION

 

We follow the accounting guidance of ASC 280 “Segment Reporting” (“ASC 280”). Reportable operating segments are determined based on the management approach. The management approach, as defined by ASC 280, is based on the way that the chief operating decision-maker organizes the segments within an enterprise for making operating decisions and assessing performance. While our results of operations are primarily reviewed on a consolidated basis, the chief operating decision-maker manages the enterprise in four reportable segments, each with different operating and potential revenue generating characteristics: (i) CAR-T Therapeutics, (ii) Cancer Vaccines, (iii) Anti-Viral Therapeutics and (iv) Other. The following represents selected financial information for our segments for the three months ended January 31, 2022 and 2021 and as of January 31, 2022 and October 31, 2021:

 

    2022     2021  
    For the Three Months Ended January 31,  
    2022     2021  
    (in thousands)  
Net loss:                
CAR-T Therapeutics   $ (1,611 )   $ (960 )
Cancer Vaccines     (1,357 )     (906 )
Anti-Viral Therapeutics     (904 )     (481 )
Other     (7 )     115  
Total   $ (3,879 )   $ (2,232 )
                 
Total operating costs and expenses   $ 3,880     $ 2,746  
Less non-cash share-based compensation     (2,354 )     (986 )
Operating costs and expenses excluding
non-cash share-based compensation		   $ 1,526     $ 1,760  
Operating costs and expenses excluding non-cash
share based compensation expense:		                
CAR-T Therapeutics   $ 669     $ 558  
Cancer Vaccines     480       538  
Anti-Viral Therapeutics     372       271  
Other     5       393  
Total   $ 1,526     $ 1,760  

 

    January 31, 2022     October 31, 2021  
    (in thousands)  
Total assets:                
CAR-T Therapeutics   $ 15,412     $ 15,068  
Cancer Vaccines     11,052       13,276  
Anti-Viral Therapeutics     8,562       7,368  
Other     212       545  
Total   $ 35,238     $ 36,257  

 

Operating costs and expenses excluding non-cash share-based compensation is the measurement the chief operating decision-maker uses in managing the enterprise.

 

The Company’s consolidated revenue of $513,000 and inventor royalties, contingent legal fees, litigation and licensing expense of $385,000 for the three months ended January 31, 2021 were solely related to our encrypted audio/video conference calling technology, which is included in our other segment. All our revenue is generated domestically (United States) based on the country in which the licensee is located.